BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.250
+0.040 (1.81%)
Apr 6, 2026, 9:45 AM EDT - Market open
BioLineRx Employees
As of December 31, 2025, BioLineRx had 24 total employees, including 20 full-time and 4 part-time employees. The number of employees decreased by 4 or -14.29% compared to the previous year.
Employees
24
Change (1Y)
-4
Growth (1Y)
-14.29%
Revenue / Employee
$49,167
Profits / Employee
-$48,958
Market Cap
10.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | -4 | -14.29% | 20 | 4 |
| Dec 31, 2024 | 28 | -51 | -64.56% | 24 | 4 |
| Dec 31, 2023 | 79 | 30 | 61.22% | 79 | 0 |
| Dec 31, 2022 | 49 | 11 | 28.95% | 49 | 0 |
| Dec 31, 2021 | 38 | 0 | - | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| Lunai Bioworks | 29 |
| Imunon | 25 |
| Theriva Biologics | 16 |
| CalciMedica | 16 |
| NewcelX | 15 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
BLRX News
- 11 days ago - BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - PRNewsWire
- 14 days ago - Earnings Scheduled For March 23, 2026 - Benzinga
- 14 days ago - BioLineRx Reports 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 14 days ago - BioLineRx (BLRX) and Others Set to Announce Earnings - GuruFocus
- 21 days ago - BioLineRx to Report 2025 Annual Results on March 23, 2026 - PRNewsWire
- 4 months ago - BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall - GuruFocus
- 4 months ago - BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture - GuruFocus
- 4 months ago - BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire